SCARF2 identified as intracellular receptor guiding hepatitis B virus to the nucleus
This article reports the discovery that scavenger receptor class F member 2 (SCARF2) functions as an intracellular receptor for hepatitis B virus (HBV). While the cell-surface receptor NTCP is known to bind HBV via the preS1 region of its large envelope protein, the subsequent transport process to the nucleus has been poorly understood. The study identifies SCARF2 as a single-pass transmembrane protein that binds to a downstream preS1 region through its N-terminal EGF-like domains 4–6, directing internalized HBV to nuclear pore complexes and facilitating nucleocapsid release from endosomes.
Key quotes
Scavenger receptor class F member 2 (SCARF2), a single-pass transmembrane protein, functions as an intracellular receptor for HBV.
SCARF2 binds to a preS1 region downstream of the NTCP binding site through its N-terminal epidermal growth factor (EGF)-like domains 4–6.
Li et al. identified SCARF2 as an intracellular receptor for HBV entry that directs internalized HBV to nuclear pore complexes and facilitates nucleocapsid release from endosomes.
From the article
You might also wanna read
Study identifies MD-1 as endogenous agonist for orphan receptor GPRC5B, linking macrophages to adipocyte signaling
This article describes research identifying MD-1 as an endogenous agonist for the orphan G protein-coupled receptor GPRC5B. Using a virion-b
scim.ag·19d agoEfficient mRNA delivery to resting T cells to reverse HIV latency
Phase 3 Trials Show Bepirovirsen Achieves Functional Cure for Hepatitis B in 20% of Patients
Phase 3 trial results published in The New England Journal of Medicine show that bepirovirsen, a novel antisense oligonucleotide targeting h
mdsc.pe·2d agoTROP2 targeting reveals therapy-driven cell state dynamics in colorectal cancer
Antibody-ligand motif optimization enables multitarget switchable CAR-T therapy against solid tumors
This article presents a research study on optimizing a multitarget switchable CAR-T (sCAR-T) strategy to overcome antigenic heterogeneity an
New plasma proteomics model improves thrombosis risk prediction in cancer patients and identifies IL-17-driven endothelial activation as therapeutic target
This article presents research by Karagkouni and colleagues who developed a new cancer-associated venous thromboembolism (VTE) prediction mo
scim.ag·16d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.